Platinum-resistant ovarian cancer: mirvetuximab soravtansine benefits are maintained in patients who require dose modifications

June 20, 2024 9:00 am

The following article is provided by The Clearity Foundation to support women with ovarian cancer and their families. Learn more about The Clearity Foundation and the services we provide directly to women as they make treatment decisions and navigate emotional impacts of their diagnosis.

As presented at the ESMO Gynaecological Cancers Congress 2024 (Florence, 20–22 June), a post-hoc analysis of the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial in patients with high folate receptor alpha (FRalpha), platinum-resistant ovarian cancer revealed that even those who required treatment dose modifications achieved clinically meaningful improvements with the antibody–drug conjugate (ADC) mirvetuximab soravtansine (MIRV) compared with investigator’s choice of chemotherapy (Abstract 44O). Similar proportions of patients required dose modifications in each arm – 124 (55%) patients with MIRV and 114 (50%) with standard chemotherapy – and in these patients, progression-free survival was significantly longer with MIRV (hazard ratio [HR] 0.58; 95% confidence interval [CI] 0.43–0.78; nominal p=0.0002). MIRV also showed benefits over chemotherapy in overall survival (HR 0.45; 95% CI 0.30–0.68; nominal p=0.0001) and objective response rate (60% versus 26%, respectively).

Figure. In patients with platinum-resistant ovarian cancer who required dose modifications, progression-free survival improved with MIRV versus standard chemotherapy in the MIRASOL trial (ESMO Gynaecological Cancers Congress 2024, Abstract 44O)

Rates of grade ≥3 treatment-emergent adverse events (TEAEs) and serious AEs were lower with MIRV (53% and 24%, respectively) versus standard chemotherapy (72% and 39%, respectively). TEAE-related treatment discontinuations occurred in 10% of patients receiving MIRV and 22% of patients receiving standard chemotherapy.

“The results of this analysis strengthen the unprecedented primary findings from the trial published last year (N Engl J Med. 2023;389:2162–2174),” comments Dr Robert L. Coleman from Texas Oncology, TX, USA. “Modifying the dose to keep within the therapeutic index is a balancing act and has the potential to lead to delivery of ineffective treatment. In the MIRASOL trial, although dose modifications were required by at least half of the patients in each treatment arm, they did not negatively impact efficacy and MIRV sustained its survival benefits over standard chemotherapy,” he says. Coleman continues: “We know that some issues raised by the MIRASOL trial still need to be investigated further, such as its lack of an ethnically diverse population. However, advantages in overall survival have been extremely difficult to show in ovarian cancertrials, because of the extent of crossover therapies available, and this makes the results seen with MIRV in the MIRASOL trial all the more impressive.”

Coleman finishes by noting that: “In gynaecological cancers, tisotumab vedotin was the first ADC to be approved for patients with cervical cancer; MIRV is the first ADC approved for ovarian cancer patients. The success of these two agents has infused tremendous enthusiasm for the development of other ADCs, broadening tissue targets and cytotoxic payloads. The developmental landscape holds new promise to improve the outcomes of patients with these difficult-to-treat types of gynaecological cancer and that can only be good news.”

The expanding role of ADCs in ovarian cancers will be discussed in an educational session at the Congress on Saturday.

Don’t miss

Banerjee S, et al. Safety and efficacy results in patients who received dose modifications in the phase 3 MIRASOL (GOG 3045/ENGOT-ov55) trial of mirvetuximab soravtansine vs investigator’s choice chemotherapy (ICC) in platinum-resistant ovarian cancer (PROC) with high folate receptor-alpha expression. ESMO Gynaecological Cancers Congress 2024, Abstract 44O

Proffered Paper Session, 20.06.2024, h. 14:45 – 16:15, Auditorium

Expanding our therapeutic armamentarium: ADCs in the ovarian cancer field

Educational Session, 22.06.2024, h. 10:20 – 11:50, Auditorium

This article was published by: ESMO Daily Reporter

Leave a Reply

Your email address will not be published. Required fields are marked *

Return to Blog Home Return to Clearity Foundation Home